Aclarion (NASDAQ:ACON) CFO Buys $24,500.00 in Stock

Aclarion, Inc. (NASDAQ:ACON) CFO Gregory Gould bought 10,000 shares of the stock in a transaction that occurred on Friday, August 14th. The shares were purchased at an average cost of $2.45 per share, for a total transaction of $24,500.00. Following the completion of the acquisition, the chief financial officer owned 60,000 shares of the company’s stock, valued at $147,000. This trade represents a 20.00% increase in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available at this link.

Aclarion Trading Down 2.9%

Shares of NASDAQ ACON opened at $2.69 on Friday. Aclarion, Inc. has a twelve month low of $1.95 and a twelve month high of $12.03. The firm has a 50-day moving average of $2.67 and a two-hundred day moving average of $2.97. The company has a market capitalization of $7.75 million, a price-to-earnings ratio of -0.36 and a beta of 1.21.

Aclarion (NASDAQ:ACON) last released its earnings results on Thursday, August 6th. The company reported ($1.12) EPS for the quarter, missing analysts’ consensus estimates of ($1.05) by ($0.07). Aclarion had a negative return on equity of 59.34% and a negative net margin of 10,948.81%.The business had revenue of $0.03 million during the quarter, compared to the consensus estimate of $0.03 million. As a group, research analysts predict that Aclarion, Inc. will post -4.51 earnings per share for the current year.

Wall Street Analyst Weigh In

Several equities research analysts have recently weighed in on the company. Weiss Ratings raised Aclarion from a “sell (e)” rating to a “sell (e+)” rating in a research note on Wednesday, August 5th. Wall Street Zen upgraded Aclarion from a “sell” rating to a “hold” rating in a research report on Saturday, June 20th. Finally, Ascendiant Capital Markets lifted their price target on Aclarion from $7.00 to $7.50 and gave the stock a “buy” rating in a research note on Friday, May 29th. One research analyst has rated the stock with a Buy rating and one has assigned a Sell rating to the stock. According to data from MarketBeat, the company presently has a consensus rating of “Hold” and an average price target of $7.50.

Aclarion Company Profile

Aclarion, Inc, a healthcare technology company, leverages for Magnetic Resonance Spectroscopy (MRS) in the United States. It develops NOCISCAN Post-Processor suite of software applications comprising NOCICALC that receives the raw un-processed NOCISCAN MRS exam data and post-processes that raw data into final spectra and performs various degenerative pain biomarker; and NOCIGRAM, a clinical decision support software. The company was formerly known as Nocimed, Inc and changed its name to Aclarion, Inc in December 2021.